

SUCCESSFUL TREATMENT OF ACUTE SEVERE ULCERATIVE COLITIS WITH STEROID SPARING REGIMEN: CONCURRENT INDUCTION WITH VEDOLIZUMAB, CYCLOSPORINE AND AZATHIOPRINE

Talha A. Malik

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

A case report describes the use of concurrent triple therapy with cyclosporine, vedolizumab, and azathioprine for acute severe ulcerative colitis in a steroid-intolerant patient who achieved clinical remission.

KEY POINTS

- A 22-year-old male with left-sided ulcerative colitis presented with acute severe disease featuring 20 watery bloody bowel movements daily, 12 kg weight loss over 6 months, and had previously failed infliximab and adalimumab.
- The patient had developed severe peripheral neuropathy on steroids requiring discontinuation, making him steroid-intolerant.
- Concurrent induction therapy with intravenous vedolizumab 300 mg, intravenous cyclosporine, and oral azathioprine was initiated on admission.
- The patient achieved clinical remission by day 12 and maintained remission at 1 week and 6 weeks post-discharge on the triple therapy regimen.
- The authors suggest this combination represents a potential rescue therapy option for acute severe ulcerative colitis patients who are steroid-intolerant.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflif.eu/search/d/7058db02-743b-11ee-8ba1-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.